TG Therapeutics (TGTX) Presents Encouraging Data from TG-1101 Phase 1b in NMO, NMOSD
Tweet Send to a Friend
TG Therapeutics, Inc. (Nasdaq: TGTX) announced the presentation of data from a Phase Ib open label study of TG-1101 (ublituximab) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
